NGNE Neurogene Inc Total Business Assets

NGNE (Neurogene Corp) - company brandmark

The daily price action for Neurogene Inc. (NGNE), which currently stands at 270.87, confirms the operational efficiency of its partner facilities and sterile zones. The business is built upon the unique EXACT system for precision gene delivery, creating a formidable technological moat. The management model relies on outsourcing drug manufacturing and conducting tests through third-party contractors, which minimizes capital expenditure.

Cumulative Company Assets: Neurogene Inc. (NGNE) for 02/21/2024 - 10/30/2026

Analytical breakdowns and data insights for company Neurogene Corp (NGNE)

- stock value and consensus price forecast:
Market Price neurogene.com|NGNE - Price Target Chart
- market capitalization data:
Market Capitalization Neurogene Therapeutics|NGNE - Enterprise Value
- book capitalization information:
Net Asset Value per Share Neurogene|NGNE - Company Net Assets|Market Capitalization to Book Value Ratio neurogene.com|NGNE - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Neurogene Inc.|NGNE - Long-Term Debt to Equity|Current Liabilities to Capital Neurogene Therapeutics|NGNE - Company Debts|Debt to Book Value Ratio Neurogene Therapeutics|NGNE - Company Long-Term Debts|Short-Term Debt Neurogene|Quick Ratio neurogene.com
- company profitability and valuation multiples indicators:
NGNE - Company Net Income
Basic company analysis:neurogene.com
Manufactured products of Neurogene

Fundamental stock selection requires analyzing the actual value of business resources to assess market overvaluation. Total assets measure aggregate capital and liabilities, calculated reversely via ROA for the operational monitoring of accruals. For Neurogene Inc. (NGNE), this metric reflects fundraising efficiency and the capitalization of intellectual property rights during clinical trials. The trend on the total assets chart allows for an assessment of the biotech startup's financial stability.

Direct competitors

Company Assets biogen.com (BIIB)|Aggregate Company Assets Neurocrine Biosciences, Inc.|Total Business Assets RGC (Regencell Bioscience Ltd)|Company Total Assets AXSM|ACAD - Company Assets|Xenon Pharmaceuticals - Cumulative Company Assets|Company Total Assets vikingtherapeutics.com VKTX|SUPN - Aggregate Company Assets|Aggregate Asset Value CPRX (Catalyst Pharma)|Denali Therapeutics Inc (DNLI) - Aggregate Company Assets|Company Assets Harmony Corp (HRMY)|Aggregate Company Assets Biohaven Ltd.|Total Business Assets AMLX (amylyx.com)|Company Total Assets TRVI|PRAX - Company Assets|Anavex Corp - Cumulative Company Assets|Company Total Assets CeriBell EEG CBLL|PRTA - Aggregate Company Assets|Aggregate Asset Value ALEC (Alector, Inc.)|Annexon (ANNX) - Aggregate Company Assets|Company Assets Omeros (OMER)|ACIU (AC Immune Corp) - Company Total Assets|VYGR - Company Balance Sheet Assets|Company Total Assets NMRA|SCLX - Company Assets|Aggregate Company Assets Tevogen Bio TVGN|ACOG: Total Business Assets|Cognition Therapeutics, Inc. - Company Total Assets|Company Assets Inhibikase Pharma|SAVA (Cassava Sciences, Inc.) - Cumulative Company Assets|Assertio - Aggregate Asset Value|COYA (Coya Therapeutics Inc) - Company Total Assets|VistaGen Therapeutics Inc (VTGN) - Company Total Asset Base|Aggregate Company Assets Ovid Therapeutics Inc. (OVID)|Acumen Pharmaceuticals, Inc - Total Business Assets|Company Total Assets CRVO (CervoMed Inc.)|ATHE - Cumulative Company Assets|CLNN: Cumulative Company Assets|Company Total Asset Base PepGen Inc. PEPG|Jupiter Neurosciences (JUNS) - Aggregate Company Assets|Total Business Assets RLMD|ANVS (Annovis Bio, Inc.) - Company Total Assets|GRCE - Company Balance Sheet Assets|Aggregate Company Assets Firefly Neuroscience (AIFF)|anewmeds.com - Total Business Assets|Company Total Assets NRSN (NeuroSense Therapeutics Ltd.)|Reviva Pharmaceuticals, Inc. (RVPH) - Company Assets|MTVA - Aggregate Company Assets|NRXS (neuraxis.com) - Total Business Assets|HSDT: Company Total Assets|Company Assets Passage Bio (PASG)|Cumulative Company Assets NEUP|Company Total Assets Minerva|Aggregate Company Assets Athira Pharma, Inc. (ATHA)|ADXN (addextherapeutics.com) - Aggregate Asset Value|Aggregate Company Assets Alzamend Neuro ALZN|Cyclerion Therapeutics Inc. (CYCN) - Company Assets|PTIX - Aggregate Company Assets|KTTA (Pasithea Therapeutics) - Total Business Assets|CRGT: Company Total Assets|Company Assets avenuetx.com (ATXI)|Cumulative Company Assets BCLI|Company Total Assets Cara Therapeutics Inc.|Aggregate Company Assets Chromocell Therapeutics Corporation (CHRO)|ELYM (eliemtx.com) - Aggregate Asset Value|Aggregate Company Assets Intra-Cellular Therapies, Inc. ITCI|longboardpharma.com (LBPH) - Company Assets|Marinus Pharmaceuticals, Inc. - Company Total Assets|Company Balance Sheet Assets NKGen Biotech Inc (NKGN)|NRBO: Company Total Assets|Company Assets Sage Therapeutics Inc (SAGE)|Aggregate Company Assets Synaptogenix, Inc.|Total Business Assets TRVN (trevena.com)|Company Total Assets VIGL|WENA - Company Assets|Cerevel - Cumulative Company Assets